Navigation Links
Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
Date:5/21/2009

nited States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer.(i) In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The Dimebon program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

(i) American Cancer Society

    Contacts:
    Medivation, Inc.                                WeissComm Partners
    Patrick Machado,
'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
11. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Lake City, UT (PRWEB) July 25, 2014 ... basketball court surfaces for the recent Nike National ... and the current United States Junior National Tournament ... through July 25. , The flooring for these prestigious ... totaling more than 300,000 square feet of playing surface ...
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Ibuprofen and Oxcarbazepine Tablets . , The FDA ... one lot of Oxcarbazepine Tablets, by American Health Packaging (AHP), ... used for the treatment of certain types of seizures in ... recall is that Lot #142588, Expiration Date, 01/2016 of Ibuprofen ...
(Date:7/25/2014)... 2014 A new study of participants in ... are published today in Cancer , found evidence that ... who had an abnormal finding on a lung cancer screening ... life than did those who were screened and found to ... to the researchers. “We expected that participants with an abnormal ...
(Date:7/25/2014)... This is a professional and ... Galactooligosaccharides (GOS) industry in Global and China. ... industry, including definitions, applications and industry chain structure. ... are provided with a focus on history, developments, ... comparison between the international and Chinese situation is ...
Breaking Medicine News(10 mins):Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3
... , TIANJIN, China, June 3 ... by Pfizer Inc. as the 2008 Top Intermediates CMO,Award, ... and drug product,facility, despite the current challenging economic environment. ... of Chemical,Development and is ready to help expand and ...
... It, Too! , , ATLANTA, June 3 We,ve all ... magazines ... celebrity moms flaunting their beautiful beach bodies in bikinis. ... which leaves the rest of us wondering how they got so ... trainer Susie Shina gained weight after having kids. The extra pounds ...
... 3 Gene Network Sciences, Inc. (GNS) today announced ... The University of Connecticut Health Center,s Carole ... parties will incorporate genetic, genomic and clinical data ("3-D ... be used to identify the best treatments for individual ...
... MINNEAPOLIS, June 3 ATS Medical, Inc. (Nasdaq: ... surgery products and services, today announced participation in the ... Meeting in San Francisco on June 3-6, 2009. ... surgeons from around the world whose interests include the ...
... ... , ... (Vocus) June 3, 2009 -- Morehead Associates will host a webinar on ... , ,Retaining skilled, engaged physicians is critical to the success of health systems across ...
... ... products and other services. , ... San Jose, Calif. (PRWEB) June 3, 2009 -- The Glowan Consulting Group, ... a new on-line store allowing clients and partners to purchase their suite of Leadership ...
Cached Medicine News:Health News:Asymchem Continues to Maintain a Good Running Posture, Despite Economic Crisis 2Health News:Asymchem Continues to Maintain a Good Running Posture, Despite Economic Crisis 3Health News:Asymchem Continues to Maintain a Good Running Posture, Despite Economic Crisis 4Health News:Celebrity Moms Make Headlines in Their New Bikinis 2Health News:Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Center's Neag Comprehensive Cancer Center 2Health News:Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Center's Neag Comprehensive Cancer Center 3Health News:ATS Medical Announces Participation in the International Society for Minimally Invasive Cardiothoracic Surgery Meeting 2Health News:ATS Medical Announces Participation in the International Society for Minimally Invasive Cardiothoracic Surgery Meeting 3Health News:ATS Medical Announces Participation in the International Society for Minimally Invasive Cardiothoracic Surgery Meeting 4Health News:Morehead Webinar on Driving Physician Retention through Engagement 2Health News:Glowan Consulting Announces New On-Line E-Commerce Site 2
(Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)...  AMETEK, Inc. (NYSE: AME ) today ... as Vice President and General Manager, Engineered Medical Components, ... "I am pleased that Kurt has joined ... experience, especially in the medical device industry, and we ... growth and success of our medical components businesses," commented ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... July 22, and OSAKA, Japan, July 23 ... Takeda Global Research & Development Center, Inc., a wholly ... U.S. Food and Drug Administration (FDA) that the FDA ... for the fixed-dose combination (FDC) of alogliptin and ACTOS((R)) ...
... , MENLO PARK, Calif., July 22 Apieron, ... positive coverage policy for the measurement of exhaled nitric oxide ... peer-reviewed evidence is sufficient to support benefit coverage for the ... the measurement of exhaled nitric oxide is considered medically necessary ...
Cached Medicine Technology:Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) 2Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) 3CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment 2
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr...
... Combines BchiVac V-500, water-cooled secondary condenser ... housing Model V-500 is a powerful PTFE ... vacuum applications. Applications Ideally ... rotary evaporators Laboratory vacuum source ...
... secondary condenser to trap residual solvent vapors ... vacuum pump designed to handle most vacuum ... for use with up to two rotary ... instruments including vacuum ovens, concentrators, gel dryers, ...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
Medicine Products: